LONDON Jan 24 GlaxoSmithKline said on
Friday the first of its phase three studies into the combination
of Tafinlar and Mekinist to treat melanoma, the deadliest form
of skin cancer, had met its main goal.
The results, along with further data expected from the
study, will increase the body of evidence on the safety and
efficiacy of the combination, the British company said.
The combined use of Tafinlar, also known as dabrafenib, and
Mekinist, or trametinib, was given the green light from the Food
and Drug Administration (FDA) in the U.S. earlier this month.